IL-13 mediates IL-33–dependent mast cell and type 2 innate lymphoid cell effects on bronchial epithelial cells - 03/07/15
| Genentech, Inc supported this research. |
|
| Disclosure of potential conflict of interest: D. R. Nagarkar and R. Soriano are employed by Genentech, Inc, and receive stock/stock options as part of compensation for employment. V. Ramirez-Carrozzi and R. Pappu are employed by Genentech, Inc, receive stock/stock options as part of compensation for employment, and have patent applications pending through Genentech. D. F. Choy is employed by Genentech, Inc, holds stock options for Roche Group as part of compensation for employment, and is a named inventor on planned patents related to a diagnostic that may predict asthmatic clinical response to anti–IL-13 through Genentech. A. R. Abbas and J. R. Arron are employed by Genentech, Inc, hold stock/stock options in Roche Group as part of compensation for employment, and are named inventors on patents related to asthma diagnosis and treatment through Genentech. Z. Modrusan is employed by Genentech and has stock/stock options from Roche as part of compensation for employment. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 136 - N° 1
P. 202-205 - juillet 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?

